

Advanced Biosimilars-first Medical Preferred Drug List

Medicare Part B Step Therapy

The CVS Caremark® Advanced Biosimilars-first Medical Preferred Drug List encourages utilization of clinically appropriate and lower net cost products within the following therapeutic drug classes. The CVS Caremark Advanced Biosimilars-first Medical Preferred Drug List applies to the listed products only and any other product may be available under a plan's medical benefit.

The listed preferred products must be used first. An exception process is in place for specific circumstances that may warrant a need for a non-preferred product. For example, this step therapy requirement does not apply to plan's members who are actively receiving treatment (i.e., members with a paid claim within the past 365 days) with non-preferred product on the CVS Caremark Advanced Biosimilars-first Medical Preferred Drug List.

Drug Class	Non-Preferred	Preferred Product(s)	Note
Acromegaly-Long Acting	Product(s)* Lanreotide Acetate	Somatuline Depot	Note
Acromegaty-Long Acting		Somatume Depot	
	Sandostatin LAR Depot		
	Signifor LAR		
Alpha-1 Antitrypsin Deficiency	Aralast	Prolastin-C	
	Glassia	Zemaira	
Antimetabolites	Alimta	Pemetrexed	
	Pemfexy		
Autoimmune Infused Infliximab	Avsola	Inflectra	
	Infliximab	Renflexis	
	Remicade		
Autoimmune Infused Other	Actemra	Entyvio	
	Cimzia	Simponi Aria	
	Ilumya	Tremfya	
	Orencia		
	Stelara IV		
Avastin/Biosimilars (Oncology)	Alymsys	Mvasi	
	Avastin	Zirabev	

^{*}Non-preferred product(s) are only available if process exception criteria are met.

^{**}Avastin Primary Preferred; Single step Byooviz, Eylea, Eylea HD, or Pavblu through Avastin. All other drugs double stepped through Byooviz, Eylea, Eylea HD, or Pavblu.

This list indicates the common uses for which the drug is prescribed. Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.

Your privacy is important to us. Our employees are trained regarding the appropriate way to handle your private health information. ©2025 CVS Caremark. All rights reserved. 106-51759B 092220





Drug Class	Non-Preferred Product(s)*	Preferred Product(s)	Note
Avastin/Biosimilars (Oncology)	Vegzelma		
Botulinum Toxins	Botox	Dysport	
	Myobloc	Xeomin	
Breast Cancer MAb	Perjeta	Phesgo	
Complement Inhibitors (aHUS, gMG, PNH)		Bkemv	
		Soliris	
		Ultomiris	
Complement Inhibitors (NMOSD)	Uplizna	Bkmev Soliris	
Hematologic, Erythropoiesis Stimulating Agents (ESA)	Epogen	Aranesp	
	Mircera	Retacrit	
	Procrit		
Hematologic, Neutropenia Colony Stimulating Factors Long Acting	Fylnetra	Fulphila	
	Neulasta	Ziextenzo	
	Nyvepria		
	Rolvedon		
	Stimufend		
	Udenyca		

^{*}Non-preferred product(s) are only available if process exception criteria are met.

^{**}Avastin Primary Preferred; Single step Byooviz, Eylea, Eylea HD, or Pavblu through Avastin. All other drugs double stepped through Byooviz, Eylea, Eylea HD, or Pavblu.

This list indicates the common uses for which the drug is prescribed. Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.



Drug Class	Non-Preferred Product(s)*	Preferred Product(s)	Note
Hematologic, Neutropenia Colony Stimulating Factors Short Acting	Granix	Zarxio	
	Leukine		
	Neupogen		
	Nivestym		
	Releuko		
Hematopoietic Agents Iron	Feraheme	Ferrlecit	
	Injectafer	Infed	
	Monoferric	Sodium Ferric Gluconate	
		Venofer	
Hemophilia Factor IX Recombinant		Alprolix	
		Idelvion	
Hemophilia Factor VIII Long Acting		Adynovate	
		Altuviiio	
		Jivi	
Hemophilia Factor VIII Recombinant	Advate	Afstyla	
	Kogenate	Kovaltry	
	Novoeight		
	Nuwiq		
	Recombinate		
	Xyntha		
	Xyntha Solofuse		
Hereditary Transthyretin Amyloidosis		Amvuttra	
		Onpattro	
Immune Globulin-IV	Asceniv	Flebogamma	
	Bivigam	Gammaked	

^{*}Non-preferred product(s) are only available if process exception criteria are met.

^{**}Avastin Primary Preferred; Single step Byooviz, Eylea, Eylea HD, or Pavblu through Avastin. All other drugs double stepped through Byooviz, Eylea, Eylea HD, or Pavblu.

This list indicates the common uses for which the drug is prescribed. Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.



	Non-Preferred		
Drug Class	Product(s)*	Preferred Product(s)	Note
Immune Globulin-IV	Gammagard Liquid	Gamunex-C	
	Gammaplex	Octagam	
	Panzyga	Privigen	
Immune Globulin-SC	Cutaquig	Hizentra	
	Cuvitru		
	HyQvia		
	Xembify		
Lysosomal Storage Disorders- Gaucher Disease	VPRIV	Cerezyme	
		Elelyso	
Mitotic Inhibitors	Abraxane	Docetaxel	
		Paclitaxel	
Multiple Myeloma Proteasome Inhibitors	Empliciti	Bortezomib	
	Kyprolis		
	Sarclisa		
	Velcade		
Multiple Sclerosis (Infused)	Briumvi	Ocrevus	
	Lemtrada	Tyruko	
	Tysabri		
Ophthalmic Geographic Atrophy	Izervay	Syfovre	
Osteoarthritis, Viscosupplements Multi Injection	Gelsyn-3	Euflexxa	
	GenVisc 850	Synvisc	
	Hyalgan		
	Hymovis		

^{*}Non-preferred product(s) are only available if process exception criteria are met.

^{**}Avastin Primary Preferred; Single step Byooviz, Eylea, Eylea HD, or Pavblu through Avastin. All other drugs double stepped through Byooviz, Eylea, Eylea HD, or Pavblu.

This list indicates the common uses for which the drug is prescribed. Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.



Drug Class	Non-Preferred Product(s)*	Preferred Product(s)	Note
Osteoarthritis, Viscosupplements Multi Injection	Orthovisc		
	Supartz FX		
	Triluron		
	TriVisc		
	Visco-3		
Osteoarthritis, Viscosupplements Single Injection	Gel-One	Durolane	
	Monovisc	Synvisc-One	
Osteoporosis-Bone Density	Evenity	Prolia Zoledronic Acid	
Osteoporosis-Hypercalcemia of Malignancy	Xgeva	Pamidronate	
		Zoledronic Acid	
PD1/L1 Immune Checkpoint Inhibitors-Basal Cell & Squamous Cell	Keytruda	Libtayo	
PD1/L1 Immune Checkpoint Inhibitors-NSCLC	Imfinzi	Libtayo	
	Keytruda		
	Opdivo		
	Tecentriq		
Prostate Cancer-Luteinizing Hormone Releasing Hormone (LHRH) Agents	Camcevi	Eligard	
	Lupron Depot		

^{*}Non-preferred product(s) are only available if process exception criteria are met.

^{**}Avastin Primary Preferred; Single step Byooviz, Eylea, Eylea HD, or Pavblu through Avastin. All other drugs double stepped through Byooviz, Eylea, Eylea HD, or Pavblu.

This list indicates the common uses for which the drug is prescribed. Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.

Your privacy is important to us. Our employees are trained regarding the appropriate way to handle your private health information. ©2025 CVS Caremark. All rights reserved. 106-51759B 092220



Drug Class	Non-Preferred Product(s)*	Preferred Product(s)	Note
Prostate Cancer-Luteinizing Hormone Releasing Hormone (LHRH)	Trelstar		
	Zoladex		
Prostate Cancer-Luteinizing Hormone Releasing Hormone (LHRH) Antagonist Agents		Firmagon	
Retinal Disorders Agents-(ARMD) Age-Related Macular Degeneration	Beovu	Avastin	**
	Cimerli	Byooviz	
	Lucentis	Eylea	
	Susvimo	Eylea HD	
	Vabysmo	Pavblu	
Rituximab	Riabni	Ruxience	
	Rituxan	Truxima	
	Riituxan Hycela		
Severe Asthma	Cinqair	Fasenra	
	Nucala	Tezspire	
		Xolair	
Trastuzumab	Herceptin	Kanjinti	
	Herceptin Hylecta	Ogivri	
	Herzuma	Ontruzant	
		Trazimera	

^{*}Non-preferred product(s) are only available if process exception criteria are met.

^{**}Avastin Primary Preferred; Single step Byooviz, Eylea, Eylea HD, or Pavblu through Avastin. All other drugs double stepped through Byooviz, Eylea, Eylea HD, or Pavblu.

This list indicates the common uses for which the drug is prescribed. Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.